Targeted Radioisotope Therapy

Targeted radioisotope therapy delivers a radioactive medicine to cells carrying a chosen target, helping focus radiation near the tumour. The medicine combines a targeting molecule with a radioisotope. After it reaches cells with the target, the radioisotope releases radiation over a short range. This approach is also called radioligand therapy; peptide receptor radionuclide therapy, or PRRT, is one form used for selected tumours.

Before treatment, your team checks whether the tumour has the target, reviews kidney function, blood counts, medicines, and pregnancy or breastfeeding status, and explains radiation-safety instructions. On treatment day, the radioligand is given through a vein. Fluids and protective medicines may be used, and you are monitored before leaving or staying in a specialist unit. The number and spacing of treatments depend on the medicine and your response.

Possible effects include nausea, vomiting, tiredness, reduced appetite, temporary pain, and changes in blood counts. Kidney or liver strain and reduced blood-cell production require monitoring. Contact the treatment team promptly for fever, unusual bleeding, severe vomiting, very little urine, marked weakness, or symptoms of an allergic reaction. Follow instructions about close contact, body fluids, hygiene, and travel because small amounts of radioactivity leave the body after treatment.

The treatment is intended to deliver radiation to target-positive disease, but response varies. Doctors assess symptoms, blood tests, scans, and the tumour target over time. Some tumours shrink, some remain controlled, and some continue to grow. Your team weighs the expected benefit against organ function, previous treatments, overall health, and available alternatives rather than promising a particular result.

A target scan or tissue result may be needed before treatment. Tell the team about kidney disease, blood disorders, medicines, supplements, and any possibility of pregnancy. Treatment selection is tumour-specific: options may be discussed for [Neuroblastoma](/conditions/neuroblastoma/), [Neuroendocrine Tumours](/conditions/neuroendocrine-tumours/), or [Prostate Cancer](/conditions/prostate-cancer/), depending on the target.

It may be considered for people whose cancer cells show the relevant target and whose health allows radioactive treatment. A nuclear-medicine specialist and oncology team review scans, pathology, prior therapy, organ function, and goals. Not every tumour carries the target, and a target can vary between tumour sites or change after treatment.

The team confirms eligibility, plans the dose, gives supportive medicines and the radioligand, monitors you during and after administration, and provides written safety advice. You may need to limit close contact for a period set by the radiation-safety team. A follow-up visit checks symptoms, blood counts, and organ function, with scans arranged when useful.

Tiredness or nausea may occur soon after administration and often improves with supportive care. Blood counts and organ tests are checked at planned intervals because some effects can appear later. Drink fluids as advised, take prescribed medicines, and report symptoms rather than changing treatment yourself. Your team will explain when normal activities and close contact are appropriate.

Radiation can affect healthy tissues, particularly organs involved in processing or excreting the medicine. Possible longer-term concerns include persistent blood-count changes, kidney or liver injury, and effects on fertility. The team explains precautions and monitoring tailored to your medicine. Ask how previous radiation or chemotherapy changes your individual risk.

Depending on the target and cancer, alternatives may include surgery, external-beam radiation, chemotherapy, hormone treatment, immunotherapy, targeted medicines, symptom-focused care, or a clinical trial. Your team compares these choices using scan findings, previous treatment, organ function, symptoms, and your preferences. [Lutetium-177](/materials/lutetium-177/) is one radioisotope used in selected targeted treatments.

Look for a coordinated service involving medical oncology, nuclear medicine, radiation safety, nursing, pharmacy, and supportive care. Ask whether the centre can confirm the tumour target, explain home precautions, arrange laboratory monitoring, and provide an urgent contact number. Bring a complete medicines list and tell the team about pregnancy plans or caregiving responsibilities.